Understand the source comparison
Follistatin-344: Strength vs Mass Comparison
Primary Mechanism Binds and sequesters myostatin (GDF-8), removing genetic brake on satellite cell activation and myofibrillar protein synthesis Direct activation of IGF-1 receptors on muscle tissue, increasing mTOR signaling and protein synthesis independent
No winner is assigned.
This page preserves a source comparison for education. It does not add a rating, recommendation or clinical judgment.
- Primary Mechanism
- Binds and sequesters myostatin (GDF-8), removing genetic brake on satellite cell activation and myofibrillar protein synthesis
- Direct activation of IGF-1 receptors on muscle tissue, increasing mTOR signaling and protein synthesis independent of mechanical load
- Binds androgen receptors selectively in muscle and bone, increasing transcription of anabolic genes without full androgenic effects
- Follistatin is the only compound that works by disinhibition rather than direct stimulation. Effect scales with training quality
- Lean Mass Gain (8 weeks)
- 1.2–3.8% in controlled trials with structured resistance training at 70–85% 1RM three times weekly
- 2.5–5.2% with suboptimal training structure. Less dependent on mechanical stimulus than follistatin
- 3.0–6.5% depending on compound and dose, with significant water retention in first four weeks
- SARMs produce the largest absolute gain, but half is transient glycogen and water. Follistatin gains are leaner
- Strength Increase
- Moderate (8–12% in compound lifts). Strength gains lag hypertrophy by 2–3 weeks due to neural adaptation delay
- High (12–18% in compound lifts). IGF-1 increases contractile protein density and enhances neuromuscular efficiency
- Very High (15–25% in compound lifts). Androgen receptor activation increases motor unit recruitment and force production
- Follistatin is suboptimal for pure strength. Better suited to hypertrophy-focused mesocycles
- Half-Life
- 3–5 hours (requires 3x weekly administration post-training to maintain myostatin suppression)
- 20–30 hours (allows daily or every-other-day administration with stable plasma levels)
- 12–24 hours depending on compound (ostarine 24h, RAD-140 16h, LGD-4033 24h)
- Follistatin's short half-life makes consistent timing critical. Missed doses result in myostatin rebound within 48 hours
- Recovery Enhancement
- Minimal. Does not improve tendon or connective tissue adaptation; injury risk increases if volume exceeds recovery capacity
- Moderate. IGF-1 supports collagen synthesis in tendons and ligaments, reducing injury risk during volume increases
- Low to Moderate. Some SARMs (ostarine) show minor joint health benefits; others (RAD-140) are neutral
- Follistatin increases muscle adaptation without proportional connective tissue strengthening. A mismatch that elevates tendinopathy risk
- Systemic Side Effects
- Low. Primary concern is off-target ActRIIB inhibition affecting cardiac muscle at doses above 500mcg weekly
- Moderate. Hypoglycemia risk if administered without carbohydrate intake; potential organ growth at prolonged high doses
- High. Suppression of endogenous testosterone, lipid profile disruption, hepatotoxicity with methylated compounds
- Follistatin has the cleanest side effect profile of the three when dosed conservatively (100–300mcg 3x weekly)